Looking At Cisco Systems’s Recent Unusual Options Activity
Deep-pocketed investors have adopted a bearish approach towards Cisco Systems (NASDAQ:CSCO), and it’s something market players shouldn’t ignore.…
Spotlight on ASML Holding: Analyzing the Surge in Options Activity
Financial giants have made a conspicuous bearish move on ASML Holding. Our analysis of options history for ASML…
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.
Nordstrom Brands Don’t Subscribe To ‘Department Stores Are Dead’ Mantra: Analyst Explains Why
Nordstrom is clearly challenged, with historically choppy gross margins, coupled with Rack's relative underperformance among the off-prices.
AMD, TSMC, Broadcom And Other Chip Stocks Hit By Biden’s Fresh AI Chip Export Restrictions: Details
Embargo on AI chip exports to Middle East triggers selloff in broader sector, including NVDA and AMD. Chip CEOs discuss AI at Taiwan's Computex.
Paycom Shares Dip Amid Leadership Changes
Paycom Software, Inc. (NYSE: PAYC), a leading provider of comprehensive, cloud-based human capital management software, announced significant leadership changes on Friday leading to decline in shares.
(PAG) – Analyzing Penske Automotive Group’s Short Interest
Penske Automotive Group’s (NYSE:PAG) short percent of float has fallen 4.75% since its last report. The company recently…
Peering Into GE Aero’s Recent Short Interest
GE Aero’s (NYSE:GE) short percent of float has risen 6.25% since its last report. The company recently reported…
(CLS) – Analyzing Celestica’s Short Interest
Celestica’s (NYSE:CLS) short percent of float has risen 31.55% since its last report. The company recently reported that…
FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.